Overview

CCRT Followed by Tegafur, Gimeracil and Oteracil Potassium in Cervical Cancer

Status:
Not yet recruiting
Trial end date:
2026-04-15
Target enrollment:
0
Participant gender:
Female
Summary
This is a single institute, single-arm, interventional trial to evaluate the efficacy and toxicity of concurrent chemoradiotherapy (CCRT) followed by Tegafur, Gimeracil and Oteracil Potassium Capsules consolidation chemotherapy in patients with locally advanced cervical cancer.
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Peking Union Medical College Hospital
Treatments:
Tegafur
Criteria
Inclusion Criteria:

Histology confirmed cervical cancer; 18-70 years old; 2018 International Federation of
Gynecology and Obstetrics (FIGO) stage IIB-IIIC2; Eastern Cooperative Oncology Group (ECOG)
score <=1 point.; Adequate marrow: neutrophile granulocyte count ≥1.5*10^9/L, hemoglobin ≥
80 g/L, platelet count ≥100*10^9/L; Normal liver and kidney function: Creatinine (Cr) < 1.5
mg/dl, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) < 2*upper limit of
normal (ULN).

Exclusion Criteria:

Prior surgery (including pelvic or para-aortic lymph nodes resection, except for tumor
biopsy), radiotherapy or chemotherapy to primary tumor or nodes; Prior malignancy;History
of previous radiotherapy to the abdomen or pelvis; Pregnancy or lactation; Active infection
with fever; Ssevere disease which may bring unacceptable risk or affect the compliance of
the trial, for example, unstable cardiac disease requiring treatment, renal disease,
chronic hepatitis, diabetes with poor control, and emotional disturbance.